<DOC>
	<DOCNO>NCT00355199</DOCNO>
	<brief_summary>Multicentric randomize phase III study compare high dos chemotherapy Rituximab follow auto-transplant HPC versus CHOP plus Rituximab first line therapy high risk patient DLBCL Non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Comparison HD Chemotherapy Followed Auto-transplant R-CHOP High Risk Patients With DLBCL .</brief_title>
	<detailed_description>Diffuse large B cell Non-Hodgkin 's lymphoma represent one frequent form lymphoma . Its clinical development progress rapidly characterized biphasic survival curve patient complete remission ( consider cure ) patient relapse . This last group subject 25 % -33 % chance long free disease survival treat second line therapy high dose chemotherapy plus autologous transplant PBPC . Therefore order achieve improvement overall survival patient DLBCL , necessary increase number complete remission first line therapy . The aim R-HDS study , multicentre randomize phase III trial , evaluate compare efficacy safety intensive condition regimen high intensity chemo-immunotherapy ( R-HDS ) plus autologous transplantation versus CHOP condition regimen plus Rituximab patient unfavorable prognosis diagnosis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis DLBCL CD20+ . Patients Ann Arbor classification Bbulk &gt; = II Patients age 1865 ageadjusted IPI 23 ECOG performance status 03 patient age 6165 IPI 3 , 4 , 5 ECOG performance status 02 . The disease stage criterion must document instrumental examination bone marrow biopsy . Hematology parameter one week start study follow : Hb &gt; = 9 g/dl , WBC &gt; = 3 x 10exp9/l , neutrophil &gt; = 1.5 x 10exp9/l , PLT &gt; = 100 x 10exp9/l . Patients pulmonary DLCO &gt; = 50 % cardiac EF &gt; = 40 % . Voluntary write informed consent must sign recruitment , understanding consent may withdraw subject time without prejudice future medical care . Patients must inform risk sterility must agree use contraception duration study . Male subject opportunity freeze seminal fluid . Diagnosis different describe . Patients concomitant , serious uncontrolled illness cardiopathy ( i.e . congestive cardiopathy , ischemic hearth disease , cardiac arrhythmia control therapy , IMA last six month , hearth disease NYHA class III IV ) , hepatopathy relate lymphoma ( bilirubin &gt; = 2 mg/dl , ALT &gt; = 2.5 time normal value , alkaline phosphatase &gt; =2.5 time upper limit ) , kidney insufficiency relate lymphoma ( creatinine &gt; =2 mg/dl ) . Patients affect opportunistic infection positive serology HIV , HCV , HbsAg ( case normal level hepatic enzyme show active viral replication document HBVDNA exclude randomization ; patient HBV+ enrol receive prophylaxis lamivudina one week start chemotherapy . These patient monitor twice month HbsAg , HBCab , HBVDNA ) . Patients another type cancer exception make skin cancer ( melanoma `` situ '' cervical cancer include ) . Patient history anaphylaxes generally patient serious allergic reaction serum infusion . Patient uncontrolled epilepsy , CNS disorder psychiatric problem , accord investigator , likely interfere participation clinical study ( i.e . signing informed consent , therapy compliance ) . Inability attend followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>R-HDS</keyword>
	<keyword>R-CHOP14</keyword>
</DOC>